Day One

Tuesday  August 31 2021

Day Two

Wednesday  September 1 2021

8.00am-6.00pm EDT | 5.00am-3.00pm PDT

DAY 1 PLENARY SESSIONS:

8:00 am Registration

8:15 am Honorary Keynote Presentation

8:45 am Your future CAR-TCR Patient Success-Stories, Delivered by Lonza

  • Etyan Abraham VP, Head of Personalized Medicine Business Unit , Lonza
  • Joe Garrity Head of Autologous Cell Therapy; Associate Director, Commercial Development, Lonza

9:15 am Industry Leaders’ Fireside Chat

  • Adrian Bot Vice President - Scientific Affairs & Translational Medicine, Kite Pharma Inc
  • Stefan Hendriks Global Head of Cell & Gene, Novartis Oncology
  • Kristen Hege Senior Vice President - Early Clinical Development, Hematology, Oncology & Cell Therapy, Bristol-Myers Squibb Co.
  • Barbra Sasu Chief Scientific Officer, Allogene Therapeutics
  • Stanley Frankel CMO, Cytovia Therapeutics

10:00 am Late Breaking Abstracts

  • Adrian Bot Vice President - Scientific Affairs & Translational Medicine, Kite Pharma Inc
  • Eric Ostertag Chief Executive Officer, Poseida Therapeutics

Synopsis

Adrian Bot will be presenting UNPUBLISHED DATA: Major Mechanisms and Strategies to Overcome CAR-T Cell Treatment Resistance

Eric Ostertag will be presenting UNPUBLISHED DATA: P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer

Download The Event Guide To See Full Sessions Details

10:30 am Speed Networking

DAY 2 PLENARY SESSIONS:

8:15 am Registration

8:45 am Genetic Programming of the Immune System Based on a Comprehensive Approach for Cancer Therapy

  • Richard Koya Professor of Medicine, University of Chicago School of Medicine

9:15 am Driving Commercial Excellence for CAR-T

  • Faruk Abdullah Senior Managing Director, EVERSANA Management Consulting

9:45 am Amassing a Decade of Experience in the Commercialization of a Cellular Therapy Product

10:15 am Next Generation Leaders Fireside Chat

DAY 1 TRACKS:

11:30am-5.30pm

 Discovery   Translation Clinical Management Early Phase
Development
Manufacturing Logistics Market Access

Must-Attend Talks

Laura Deschenes Takeda

Case Study: Considerations, Challenges, and Infrastructure of an Autologous and Allogeneic Cell Therapy Supply Chain
Laura Deschenes, Head, Supply Chain & Operations, Cell Therapies, Takeda

Tam-Soden

Integrating Flexibility in CMC Strategy to Manage Risk and Enable Process Improvement at Commercial Scale
Tam Soden, Executive Director & Global Head of Quality Control, Kite: A Gilead Company

Delfi Krishna

Optimizing the End-to-End Patient Journey for Autologous Ex-Vivo T-Cell Therapies During Early Clinical Development
Delfi Krishna, Head of Strategic Operations, Immatics

Adaptimmune Limited, 101 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY, UK. 13/7/15. Helen Taylor-Martin pictured at the Adaptimmune offices in Abingdon
Picture: Ric Mellis
13/7/2015 Abingdon UK
Catchline: Adaptimmune

Achieving Commercial Foresight: What
You Need to Know, and When to Take Action to Achieve Commercial Success

Helen Tayton-Martin, CBO, Adaptimmune

DAY 2 TRACKS:

11.30am-5.30pm

 Discovery   Translation Clinical Management Early Phase
Development
Manufacturing Logistics Market Access

Must-Attend Talks

axel hoos

Industrializing Solid Tumor Cell Therapies as Mainstream Medicines

Axel Hoos, SVP, R&D Governance Chair & Therapeutic Area Head Oncology, GSK

Aaron Foster Sana

Developing Platforms to Deliver an Integrating Transgene In-Vivo with Specific Targeting to T-Cells
Aaron Foster, VP Immunology, Sana Biotechnology

Roddy o'connor

Optimizing Fuel Selection with Enriched Media to Yield ‘Super Metabolizing’ CAR-T Cell Populations, Equipped for Solid Tumor Survival
Roderick O’Connor, Research Assistant Professor of Pathology and Laboratory Medicine, University of Pennsylvania

Michael-Klichinsky

Translating CAR-Macrophages into the Clinic, with Restricted Anti-Tumor Phenotypes
Michael Klichinsky, Co-Founder & VP Discovery Research, Carisma Therapeutics